Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)

被引：0
|
作者：
Brandes, J.
Kudrow, D.
Klise, S. [1 ]
Krege, J. H.
Case, M. G.
Raskin, J.
Khanna, R. [2 ]
Vasudeva, R.
机构：
[1] Eli Lilly & Co, Missoula, MT USA
[2] Eli Lilly & Co, Windlesham, Surrey, England
来源：
HEADACHE | 2019年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P157
引用
收藏
页码：121 / 121
页数：1
相关论文
共 50 条
  • [1] Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine Over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)
    Brandes, Jan
    Kudrow, David
    Klise, Suzanne
    Krege, John H.
    Case, Michael
    Raskin, Joel
    Khanna, Rashna
    Vasudeva, Raghavendra
    [J]. NEUROLOGY, 2019, 92 (15)
  • [2] Long-Term Cardiovascular Safety of Lasmiditan for the Acute Treatment of Migraine for up to One Year: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)
    Rosen, N. L.
    Mathew, P. G.
    Buchanan, A. S.
    Baygani, S.
    Hochstetler, H.
    Khanna, R.
    [J]. HEADACHE, 2020, 60 : 111 - 111
  • [3] LONG-TERM CARDIOVASCULAR SAFETY OF LASMIDITAN FOR THE ACUTE TREATMENT OF MIGRAINE FOR UP TO ONE YEAR: INTERIM RESULTS OF AN OPEN-LABEL PHASE 3 STUDY (GLADIATOR)
    Buchanan, Andrew
    Baygani, Simin K.
    Rosen, Noah
    Mathew, Paul G.
    Hochstetler, Helen
    Khanna, Rashna
    [J]. CEPHALALGIA, 2020, 40 : 49 - 50
  • [4] Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)
    Brandes, Jan Lewis
    Klise, Suzanne
    Krege, John H.
    Case, Michael
    Khanna, Rashna
    Vasudeva, Raghavendra
    Raskin, Joel
    Pearlman, Eric M.
    Kudrow, David
    [J]. CEPHALALGIA, 2019, 39 (11) : 1343 - 1357
  • [5] Fremanezumab Long-Term Efficacy and Safety: Interim Results of a One-Year Study
    Goadsby, P.
    Yeung, P. P.
    Blankenbiller, T.
    Grozinski-Wolff, M.
    Yang, R.
    Ma, Y.
    Ning, X.
    Aycardi, E.
    [J]. HEADACHE, 2018, 58 : 166 - 166
  • [6] Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION study
    Ashina, M.
    Roos, C.
    Ayer, D. W.
    Ruff, D.
    Krege, J. H.
    Li, L. Q.
    Komori, M.
    [J]. HEADACHE, 2022, 62 : 113 - 114
  • [7] Long-Term Treatment With Lasmiditan in Patients With Migraine: Results From the Open-Label Extension of the CENTURION Study
    Ashina, M.
    Roos, C.
    Ayer, D.
    Ruff, D.
    Krege, J.
    Li, L. Q.
    Komori, M.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [8] A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine
    Croop, Robert
    Berman, Gary
    Kudrow, David
    Mullin, Kathleen
    Thiry, Alexandra
    Lovegren, Meghan
    L'Italien, Gilbert
    Lipton, Richard B.
    [J]. CEPHALALGIA, 2024, 44 (04)
  • [9] Long-term efficacy and safety with zonisamide: Interim analysis of an open-label study
    Wroe, S
    Brodie, MJ
    [J]. EPILEPSIA, 2005, 46 : 118 - 118
  • [10] A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
    Angelo Camporeale
    David Kudrow
    Ryan Sides
    Shufang Wang
    Annelies Van Dycke
    Katherine J. Selzler
    Virginia L. Stauffer
    [J]. BMC Neurology, 18
12345